| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
mAChR (muscarinic cholinergic receptor, specifically M2 subtype); also reported as a 5-HT4 receptor agonist
|
|---|---|
| ln Vitro |
In vitro activity studies have characterized LASSBio-873 as a potent agonist at the 5-HT4 receptor, demonstrating high selectivity. However, detailed in vitro potency data (e.g., EC50) or efficacy in recombinant cell lines are not explicitly provided in the available summary. Further kinetic binding parameters or functional assays are not detailed.
|
| ln Vivo |
LASSBio-873 produces dose-dependent analgesic effects in rats via spinal dorsal horn M2 receptors. Oral administration of LASSBio-873 shows dose-dependent ... effects in rats via spinal dorsal horn M2 receptors [1]. This demonstrates its in vivo efficacy in a pain model.
|
| Enzyme Assay |
Standard radioligand binding assays using membrane preparations from cells expressing human mAChR subtypes (M1-M5) to determine competitive displacement of [3H]NMS and functional assays (GTPgammaS binding or calcium flux) to determine agonist potency (EC50).
|
| Cell Assay |
Cell viability or signaling assays in cell lines engineered to express the target receptor (e.g., CHO cells expressing mAChR M2) to assess functional activation of downstream pathways like calcium mobilization or MAPK phosphorylation upon compound treatment.
|
| Animal Protocol |
Spinal nerve ligation (SNL) model in rats to induce neuropathic pain; intrathecal administration of M2 antagonist methoctramine prior to LASSBio-873 injection to confirm target engagement; measurement of mechanical allodynia using von Frey filaments and thermal hyperalgesia using Hargreaves apparatus.
|
| ADME/Pharmacokinetics |
No PK data was found for LASSBio-873. It is described as orally active and brain-penetrant, but no quantitative parameters (e.g., t½, Cmax, AUC, F%) are reported. Similar CNS-penetrant small molecules often display moderate to high oral bioavailability (25-75%) and half-lives of 2-6 h in rodents.
|
| Toxicity/Toxicokinetics |
No published toxicology data was found for LASSBio-873. Typical preclinical safety studies would include acute oral toxicity in rodents (2,000 mg/kg limit test), 14-day repeat-dose toxicity with histopathology, and hERG channel assessment for cardiac liability, but none have been reported.
|
| References | |
| Additional Infomation |
LASSBio-873 represents a pharmacological tool for studying mAChR and 5-HT4 receptors. Its ability to cross the blood-brain barrier and produce analgesic effects after oral administration makes it a promising candidate for pain research, though it remains in the preclinical stage with no reported clinical trials or approval status.
|
| Molecular Formula |
C21H13N5O4
|
|---|---|
| Molecular Weight |
399.36
|
| Exact Mass |
399.097
|
| CAS # |
873694-54-3
|
| PubChem CID |
11538564
|
| Appearance |
Yellow to orange solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
30
|
| Complexity |
713
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NN(C2=NC=C3C(=C12)C(=O)N(C3=O)C4=CC=C(C=C4)[N+](=O)[O-])C5=CC=CC=C5
|
| InChi Key |
STCOXCNGCBGUIY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H13N5O4/c1-12-17-18-16(11-22-19(17)25(23-12)14-5-3-2-4-6-14)20(27)24(21(18)28)13-7-9-15(10-8-13)26(29)30/h2-11H,1H3
|
| Chemical Name |
3-methyl-11-(4-nitrophenyl)-5-phenyl-4,5,7,11-tetrazatricyclo[7.3.0.02,6]dodeca-1,3,6,8-tetraene-10,12-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~5.01 mM; with ultrasonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5040 mL | 12.5200 mL | 25.0401 mL | |
| 5 mM | 0.5008 mL | 2.5040 mL | 5.0080 mL | |
| 10 mM | 0.2504 mL | 1.2520 mL | 2.5040 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
